anastrozole ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
aromatase inhibitors, imidazole-triazole derivatives 210 120511-73-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • anastrozole
  • anastrazole
  • anastrol
  • arimidex
A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.
  • Molecular weight: 293.37
  • Formula: C17H19N5
  • CLOGP: 1.75
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 0
  • TPSA: 78.29
  • ALOGS: -3.65
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.06 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 27, 1995 FDA ASTRAZENECA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to bone 1105.59 11.70 468 50535 20551 63417468
Malignant neoplasm progression 829.12 11.70 616 50387 81505 63356514
Metastases to liver 615.04 11.70 324 50679 23315 63414704
Metastases to lung 483.94 11.70 226 50777 12524 63425495
Osteonecrosis 352.83 11.70 229 50774 24301 63413718
Hot flush 348.11 11.70 305 50698 50854 63387165
Breast cancer recurrent 290.63 11.70 115 50888 4226 63433793
Breast cancer metastatic 282.37 11.70 154 50849 11864 63426155
Disease progression 275.22 11.70 411 50592 122347 63315672
Bone pain 257.63 11.70 266 50737 54375 63383644
Metastases to lymph nodes 241.41 11.70 122 50881 8036 63429983
Neoplasm progression 241.38 11.70 214 50789 36214 63401805
Drug ineffective 238.79 11.70 295 50708 1044470 62393549
Breast cancer 230.72 11.70 237 50766 48146 63389873
Neutropenia 218.59 11.70 453 50550 174552 63263467
Osteonecrosis of jaw 202.74 11.70 191 50812 34932 63403087
Tumour marker increased 198.54 11.70 91 50912 4824 63433195
Ejection fraction decreased 186.65 11.70 150 50853 22182 63415837
White blood cell count decreased 184.19 11.70 369 50634 138735 63299284
Contraindicated product administered 156.02 11.70 4 50999 217644 63220375
Maternal exposure during pregnancy 154.25 11.70 5 50998 220057 63217962
Metastasis 151.66 11.70 77 50926 5120 63432899
Tooth extraction 143.08 11.70 94 50909 10170 63427849
Metastases to spine 133.89 11.70 61 50942 3188 63434831
Infusion related reaction 131.77 11.70 20 50983 245501 63192518
Pseudocirrhosis 130.77 11.70 40 50963 667 63437352
Systemic lupus erythematosus 129.87 11.70 10 50993 208908 63229111
Therapeutic product effect decreased 120.78 11.70 9 50994 193178 63244841
Synovitis 116.02 11.70 9 50994 186909 63251110
Arthralgia 114.23 11.70 815 50188 568895 62869124
Neuropathy peripheral 104.71 11.70 261 50742 113406 63324613
Bone lesion 97.25 11.70 60 50943 5821 63432198
Treatment failure 96.46 11.70 21 50982 199022 63238997
Carbohydrate antigen 15-3 increased 95.66 11.70 38 50965 1410 63436609
Metastases to pleura 92.33 11.70 38 50965 1547 63436472
Rheumatoid arthritis 91.16 11.70 45 50958 253774 63184245
Joint swelling 90.69 11.70 78 50925 327588 63110431
Osteopenia 89.03 11.70 94 50909 19691 63418328
Trigger finger 83.30 11.70 49 50954 4359 63433660
Completed suicide 82.54 11.70 10 50993 145663 63292356
Glossodynia 82.46 11.70 21 50982 178855 63259164
Osteolysis 82.16 11.70 42 50961 2832 63435187
Bone disorder 81.51 11.70 93 50910 21233 63416786
Pericarditis 79.80 11.70 7 50996 131572 63306447
Fatigue 75.56 11.70 1063 49940 886965 62551054
Pain in jaw 70.63 11.70 126 50877 43370 63394649
Vitreoretinal traction syndrome 68.80 11.70 13 50990 17 63438002
Ascites 68.74 11.70 120 50883 40608 63397411
Myalgia 67.97 11.70 265 50738 146264 63291755
Lymphoedema 66.32 11.70 63 50940 11629 63426390
Drug hypersensitivity 66.01 11.70 92 50911 310595 63127424
Tonsillar disorder 64.99 11.70 27 50976 1126 63436893
Lacrimation increased 64.13 11.70 81 50922 20550 63417469
Metastases to central nervous system 63.88 11.70 65 50938 13040 63424979
PIK3CA-activated mutation 63.77 11.70 26 50977 1033 63436986
Metastases to pelvis 63.73 11.70 21 50982 450 63437569
Nasal disorder 62.59 11.70 35 50968 2829 63435190
Wound 61.59 11.70 27 50976 163236 63274783
Acute myeloid leukaemia 60.88 11.70 72 50931 17075 63420944
Organising pneumonia 57.39 11.70 43 50960 5733 63432286
Off label use 55.94 11.70 316 50687 674146 62763873
Retinal toxicity 55.90 11.70 25 50978 1250 63436769
Sequestrectomy 55.69 11.70 22 50981 804 63437215
Arthropathy 55.60 11.70 64 50939 234728 63203291
Malignant pleural effusion 54.65 11.70 31 50972 2575 63435444
Vulvovaginal dryness 54.17 11.70 32 50971 2869 63435150
Cystoid macular oedema 53.87 11.70 26 50977 1549 63436470
Debridement 53.78 11.70 24 50979 1194 63436825
Toxicity to various agents 52.71 11.70 73 50930 247177 63190842
Abdominal discomfort 52.62 11.70 112 50891 320773 63117246
Hypersensitivity 51.55 11.70 98 50905 292587 63145432
Metastases to chest wall 51.51 11.70 19 50984 574 63437445
Osteomyelitis 51.02 11.70 82 50921 25938 63412081
Psoriatic arthropathy 50.10 11.70 7 50996 91513 63346506
Intentional product use issue 50.08 11.70 20 50983 127872 63310147
Leukopenia 48.98 11.70 155 50848 77135 63360884
Breast cancer female 48.25 11.70 57 50946 13502 63424517
Endometrial hyperplasia 47.56 11.70 20 50983 860 63437159
Metastases to the mediastinum 47.48 11.70 17 50986 471 63437548
Metastatic neoplasm 47.25 11.70 34 50969 4261 63433758
Bone sequestrum 46.42 11.70 23 50980 1451 63436568
Swelling 46.08 11.70 95 50908 275283 63162736
Irritable bowel syndrome 45.83 11.70 6 50997 82406 63355613
Second primary malignancy 45.39 11.70 43 50960 7910 63430109
Metastases to abdominal wall 45.22 11.70 12 50991 116 63437903
Fasciitis 44.56 11.70 17 50986 565 63437454
Invasive ductal breast carcinoma 44.32 11.70 40 50963 6918 63431101
Interstitial lung disease 43.75 11.70 129 50874 61779 63376240
Drug abuse 43.57 11.70 4 50999 72514 63365505
Oestradiol increased 43.53 11.70 11 50992 86 63437933
Sinusitis 43.40 11.70 72 50931 226581 63211438
Polyneuropathy 43.33 11.70 56 50947 14533 63423486
Peritoneal disorder 43.30 11.70 16 50987 486 63437533
Folliculitis 41.92 11.70 4 50999 70313 63367706
Pleural effusion 41.92 11.70 167 50836 93043 63344976
Product use issue 40.44 11.70 72 50931 220448 63217571
Excessive eye blinking 40.39 11.70 20 50983 1260 63436759
Hypotension 39.96 11.70 101 50902 272503 63165516
Pathological fracture 39.79 11.70 42 50961 8792 63429227
Discomfort 39.19 11.70 46 50957 167328 63270691
Thrombocytopenia 37.82 11.70 229 50774 150928 63287091
Dry skin 37.80 11.70 116 50887 56771 63381248
Nail disorder 37.16 11.70 49 50954 12966 63425053
Hair growth abnormal 36.04 11.70 25 50978 2956 63435063
Red blood cell count decreased 35.99 11.70 92 50911 40553 63397466
Muscle injury 35.76 11.70 5 50998 65340 63372679
Hepatic enzyme increased 34.50 11.70 69 50934 202259 63235760
Hypertensive angiopathy 34.20 11.70 9 50994 84 63437935
Drug intolerance 34.15 11.70 130 50873 308531 63129488
Musculoskeletal chest pain 34.12 11.70 61 50942 21022 63416997
Breast pain 33.00 11.70 38 50965 8760 63429259
Gene mutation 32.76 11.70 19 50984 1646 63436373
Palmar-plantar erythrodysaesthesia syndrome 32.74 11.70 63 50940 22952 63415067
Sialoadenitis 32.69 11.70 19 50984 1653 63436366
Pleural neoplasm 32.65 11.70 12 50991 359 63437660
Oestrogen receptor assay positive 32.31 11.70 13 50990 499 63437520
Tumour marker abnormal 32.15 11.70 12 50991 375 63437644
Metastases to soft tissue 32.03 11.70 10 50993 179 63437840
Uterine polyp 31.59 11.70 20 50983 2030 63435989
Dental care 31.38 11.70 16 50987 1073 63436946
Gingival swelling 31.34 11.70 27 50976 4391 63433628
Blister 31.12 11.70 35 50968 129779 63308240
Injection site pain 31.11 11.70 35 50968 129765 63308254
Metastases to spinal cord 31.01 11.70 9 50994 124 63437895
Injection site erythema 30.96 11.70 14 50989 83160 63354859
Carpal tunnel syndrome 30.87 11.70 58 50945 20759 63417260
Injection site reaction 30.83 11.70 5 50998 58519 63379500
Tendonitis 30.78 11.70 56 50947 19559 63418460
Soft tissue neoplasm 30.76 11.70 8 50995 71 63437948
Pancreatic neoplasm 30.72 11.70 14 50989 732 63437287
Portal hypertension 30.52 11.70 25 50978 3794 63434225
Metastases to skin 30.15 11.70 18 50985 1645 63436374
Intentional overdose 30.01 11.70 11 50992 74141 63363878
Mouth swelling 29.70 11.70 27 50976 4713 63433306
Loss of personal independence in daily activities 29.59 11.70 21 50982 97269 63340750
Decreased appetite 29.54 11.70 320 50683 250732 63187287
Product substitution issue 29.45 11.70 49 50954 15947 63422072
Pain 29.36 11.70 419 50584 740209 62697810
Dysgeusia 28.96 11.70 93 50910 46617 63391402
Blood alkaline phosphatase increased 28.90 11.70 88 50915 42879 63395140
Chronic inflammatory demyelinating polyradiculoneuropathy 28.47 11.70 12 50991 519 63437500
Hyperparathyroidism primary 28.19 11.70 11 50992 389 63437630
Tooth loss 28.08 11.70 31 50972 6825 63431194
Acute phase reaction 28.07 11.70 10 50993 273 63437746
Oestradiol abnormal 27.90 11.70 7 50996 53 63437966
Ischaemic stroke 27.84 11.70 51 50952 17906 63420113
Periodontal disease 27.72 11.70 17 50986 1631 63436388
Radiation skin injury 27.59 11.70 14 50989 929 63437090
Hepatic lesion 27.37 11.70 26 50977 4799 63433220
Leiomyosarcoma recurrent 27.18 11.70 5 50998 5 63438014
Vitreous detachment 26.88 11.70 18 50985 2009 63436010
Condition aggravated 26.85 11.70 201 50802 402016 63036003
Joint neoplasm 26.83 11.70 7 50996 63 63437956
C-reactive protein abnormal 26.50 11.70 3 51000 46093 63391926
Tumour marker decreased 26.35 11.70 7 50996 68 63437951
Resorption bone increased 26.30 11.70 15 50988 1259 63436760
Hair texture abnormal 26.26 11.70 24 50979 4219 63433800
Anaemia 26.22 11.70 355 50648 293075 63144944
Retinal detachment 26.21 11.70 28 50975 5941 63432078
Neutrophil count decreased 26.11 11.70 102 50901 56304 63381715
Gingivitis 26.04 11.70 33 50970 8396 63429623
Mucosal inflammation 26.04 11.70 90 50913 46838 63391181
Cardiotoxicity 26.02 11.70 33 50970 8405 63429614
Oral pain 25.90 11.70 65 50938 28329 63409690
Metastases to thorax 25.57 11.70 9 50994 237 63437782
Progesterone receptor assay positive 25.46 11.70 10 50993 360 63437659
Exposed bone in jaw 25.18 11.70 20 50983 2905 63435114
Nausea 25.16 11.70 879 50124 853592 62584427
Metastases to retroperitoneum 24.98 11.70 8 50995 156 63437863
Hormone receptor positive breast cancer 24.92 11.70 11 50992 533 63437486
Haemorrhoids 24.87 11.70 55 50948 22095 63415924
Recurrent cancer 24.81 11.70 17 50986 1970 63436049
Ovarian cancer 24.44 11.70 27 50976 5949 63432070
Metastases to peritoneum 24.35 11.70 21 50982 3421 63434598
Product use in unapproved indication 24.22 11.70 69 50934 179011 63259008
Full blood count decreased 24.18 11.70 60 50943 25964 63412055
Fibrous histiocytoma 24.12 11.70 11 50992 576 63437443
Fracture 23.56 11.70 50 50953 19534 63418485
Nail avulsion 23.54 11.70 8 50995 189 63437830
Injection site pruritus 23.44 11.70 4 50999 45112 63392907
Nail infection 23.34 11.70 18 50985 2505 63435514
Bone density decreased 23.29 11.70 42 50961 14570 63423449
Tooth disorder 23.15 11.70 62 50941 28095 63409924
Recall phenomenon 23.05 11.70 11 50992 639 63437380
Hiccups 23.04 11.70 17 50986 2214 63435805
Superinfection 22.82 11.70 18 50985 2589 63435430
Therapeutic product effect incomplete 22.75 11.70 41 50962 125015 63313004
Catheter site bruise 22.72 11.70 10 50993 481 63437538
Jaundice 22.65 11.70 63 50940 29188 63408831
Neoplasm recurrence 22.63 11.70 18 50985 2620 63435399
Cholestasis 22.40 11.70 63 50940 29371 63408648
Fibromyalgia 22.37 11.70 19 50984 80401 63357618
Osteosclerosis 22.14 11.70 21 50982 3867 63434152
Hair colour changes 21.96 11.70 19 50984 3108 63434911
Bone debridement 21.84 11.70 8 50995 237 63437782
Urticaria 21.61 11.70 65 50938 165737 63272282
Tumour flare 21.58 11.70 9 50994 379 63437640
Pneumonia 21.53 11.70 249 50754 456518 62981501
Acquired gene mutation 21.44 11.70 12 50991 971 63437048
Transient acantholytic dermatosis 21.43 11.70 6 50997 72 63437947
Polymyositis 21.42 11.70 15 50988 1801 63436218
Full blood count abnormal 21.37 11.70 65 50938 31652 63406367
Peripheral swelling 21.19 11.70 126 50877 265816 63172203
Antisynthetase syndrome 21.14 11.70 6 50997 76 63437943
Autoimmune pancreatitis 20.85 11.70 8 50995 270 63437749
Human epidermal growth factor receptor negative 20.79 11.70 5 50998 31 63437988
Diarrhoea 20.54 11.70 734 50269 714632 62723387
Type 2 diabetes mellitus 20.47 11.70 13 50990 63855 63374164
Jaw operation 20.23 11.70 11 50992 841 63437178
Cutaneous vasculitis 20.17 11.70 23 50980 5246 63432773
Cardiomyopathy 20.13 11.70 44 50959 17540 63420479
Metastases to bone marrow 20.07 11.70 9 50994 453 63437566
Papilloedema 19.95 11.70 20 50983 3940 63434079
Vertebral column mass 19.83 11.70 7 50996 186 63437833
Atypical femur fracture 19.80 11.70 23 50980 5349 63432670
Blood copper increased 19.80 11.70 4 50999 9 63438010
Joint stiffness 19.61 11.70 76 50927 41793 63396226
Asthenia 19.60 11.70 424 50579 383180 63054839
Wheezing 19.58 11.70 29 50974 95566 63342453
Henoch-Schonlein purpura 19.57 11.70 12 50991 1151 63436868
Uterine leiomyoma 19.43 11.70 30 50973 9168 63428851
Vascular purpura 19.30 11.70 13 50990 1465 63436554
Psoriasis 19.19 11.70 25 50978 86932 63351087
Overdose 18.96 11.70 40 50963 115038 63322981
Knee arthroplasty 18.84 11.70 10 50993 54196 63383823
Bone marrow failure 18.78 11.70 59 50944 29231 63408788
Spinal pain 18.73 11.70 36 50967 13103 63424916
Epistaxis 18.69 11.70 111 50892 72614 63365405
Left ventricular dysfunction 18.53 11.70 34 50969 11954 63426065
Breast mass 18.39 11.70 27 50976 7895 63430124
Jaw disorder 18.23 11.70 22 50981 5327 63432692
Septic shock 18.22 11.70 16 50987 66613 63371406
Gastrointestinal disorder 18.16 11.70 50 50953 131189 63306830
Asthma 18.10 11.70 48 50955 127513 63310506
Neoplasm malignant 18.10 11.70 59 50944 29802 63408217
Actinomycosis 18.09 11.70 11 50992 1039 63436980
Bacteriuria 18.07 11.70 11 50992 1042 63436977
Pyrexia 17.94 11.70 268 50735 470210 62967809
Carbohydrate antigen 27.29 increased 17.86 11.70 5 50998 60 63437959
Medication error 17.66 11.70 10 50993 52274 63385745
Tongue neoplasm malignant stage unspecified 17.59 11.70 10 50993 834 63437185
Osteitis 17.36 11.70 17 50986 3257 63434762
Injection site bruising 17.33 11.70 6 50997 41904 63396115
Carcinoembryonic antigen increased 17.22 11.70 13 50990 1752 63436267
Atrophic vulvovaginitis 17.21 11.70 13 50990 1755 63436264
Alopecia 17.20 11.70 373 50630 337163 63100856
Purulent discharge 17.10 11.70 20 50983 4686 63433333
Plantar fasciitis 17.09 11.70 18 50985 3757 63434262
Heart rate increased 17.05 11.70 31 50972 94207 63343812
Invasive lobular breast carcinoma 17.05 11.70 10 50993 885 63437134
Osteoporosis 17.04 11.70 91 50912 57247 63380772
Sedation 17.03 11.70 5 50998 38804 63399215
Neoplasm 17 11.70 25 50978 7320 63430699
Intraductal proliferative breast lesion 16.95 11.70 16 50987 2929 63435090
Autoimmune hepatitis 16.93 11.70 27 50976 8483 63429536
Blood pressure fluctuation 16.92 11.70 8 50995 46309 63391710
Multiple sclerosis relapse 16.77 11.70 9 50994 48469 63389550
Peripheral sensory neuropathy 16.73 11.70 25 50978 7426 63430593
Acute promyelocytic leukaemia 16.72 11.70 10 50993 917 63437102
Vaginal discharge 16.70 11.70 28 50975 9170 63428849
Disease recurrence 16.65 11.70 55 50948 27975 63410044
Joint range of motion decreased 16.57 11.70 3 51000 32425 63405594
Toothache 16.52 11.70 43 50960 19156 63418863
Endometrial hypertrophy 16.45 11.70 7 50996 310 63437709
Neuralgia 16.42 11.70 52 50951 25874 63412145
Neuroectodermal neoplasm 16.31 11.70 3 51000 3 63438016
Bronchitis 16.26 11.70 49 50954 124886 63313133
Nasopharyngitis 16.03 11.70 129 50874 254128 63183891
Infection 16.00 11.70 113 50890 229060 63208959
Breast haemorrhage 15.97 11.70 6 50997 191 63437828
Metastases to uterus 15.94 11.70 5 50998 91 63437928
Oroantral fistula 15.91 11.70 6 50997 193 63437826
Visual acuity reduced 15.91 11.70 46 50957 21780 63416239
Back pain 15.81 11.70 299 50704 263846 63174173
Metastases to adrenals 15.77 11.70 9 50994 756 63437263
Prescribed overdose 15.74 11.70 4 50999 34149 63403870
Tremor 15.72 11.70 54 50949 132185 63305834
Atrial enlargement 15.69 11.70 7 50996 348 63437671
Cardio-respiratory arrest 15.68 11.70 15 50988 59944 63378075
Musculoskeletal stiffness 15.48 11.70 86 50917 184532 63253487
Constipation 15.36 11.70 260 50743 224683 63213336
Gamma-glutamyltransferase increased 15.31 11.70 61 50942 33970 63404049
HER2 positive breast cancer 15.30 11.70 7 50996 369 63437650
Paratracheal lymphadenopathy 15.04 11.70 4 50999 39 63437980
Meningioma 14.94 11.70 17 50986 3868 63434151
Confusional state 14.87 11.70 120 50883 236260 63201759
Decreased immune responsiveness 14.85 11.70 19 50984 4882 63433137
Hyperkalaemia 14.84 11.70 13 50990 54190 63383829
Abdominal wall cyst 14.78 11.70 4 50999 42 63437977
Wrong technique in product usage process 14.72 11.70 17 50986 62323 63375696
Prescribed underdose 14.64 11.70 3 51000 29686 63408333
Hypoaesthesia teeth 14.61 11.70 4 50999 44 63437975
Incorrect dose administered 14.55 11.70 16 50987 59952 63378067
Benign lymph node neoplasm 14.49 11.70 3 51000 8 63438011
Chronic hepatitis 14.46 11.70 9 50994 887 63437132
Borrelia infection 14.33 11.70 6 50997 255 63437764
Therapeutic response decreased 14.29 11.70 17 50986 61508 63376511
Flushing 14.21 11.70 24 50979 75063 63362956
Oral surgery 14.11 11.70 10 50993 1224 63436795
Vitreous adhesions 14.07 11.70 4 50999 51 63437968
Radiation pneumonitis 14.01 11.70 11 50992 1572 63436447
Bone marrow infiltration 13.98 11.70 8 50995 676 63437343
Suicide attempt 13.97 11.70 17 50986 60901 63377118
Radicular pain 13.83 11.70 7 50996 462 63437557
Lower respiratory tract infection 13.80 11.70 57 50946 132250 63305769
Cardiac arrest 13.76 11.70 34 50969 92511 63345508
Romberg test positive 13.72 11.70 5 50998 146 63437873
Postoperative wound complication 13.64 11.70 9 50994 980 63437039
Dyspnoea exertional 13.59 11.70 89 50914 60213 63377806
Dental caries 13.52 11.70 28 50975 10751 63427268
Metastases to breast 13.38 11.70 6 50997 302 63437717
Retroperitoneal fibrosis 13.36 11.70 6 50997 303 63437716
Gingival erythema 13.35 11.70 8 50995 736 63437283
Pustule 13.32 11.70 11 50992 1688 63436331
Metastases to eye 13.31 11.70 5 50998 159 63437860
Loose tooth 13.30 11.70 15 50988 3379 63434640
Electrocardiogram QT interval 13.11 11.70 5 50998 166 63437853
Cardiac failure 13.07 11.70 119 50884 89023 63348996
Ovarian mass 13.07 11.70 8 50995 765 63437254
Squamous cell breast carcinoma 13.02 11.70 3 51000 15 63438004
Dysaesthesia 13 11.70 17 50986 4461 63433558
Urinary casts present 12.95 11.70 4 50999 69 63437950
Hypercalcaemia 12.93 11.70 51 50952 28271 63409748
Phlebitis 12.92 11.70 21 50982 6703 63431316
Rash 12.78 11.70 348 50655 560523 62877496
Meibomian gland dysfunction 12.78 11.70 5 50998 178 63437841
Madarosis 12.74 11.70 14 50989 3067 63434952
Anaphylactic reaction 12.63 11.70 21 50982 66079 63371940
Acquired porokeratosis 12.42 11.70 3 51000 19 63438000
Cutaneous sarcoidosis 12.37 11.70 6 50997 361 63437658
Diabetic hyperosmolar coma 12.33 11.70 6 50997 364 63437655
Breast cancer in situ 12.32 11.70 10 50993 1498 63436521
Chronic hepatic failure 12.31 11.70 7 50996 584 63437435
Oral disorder 12.30 11.70 24 50979 8830 63429189
Urinary tract infection staphylococcal 12.27 11.70 6 50997 368 63437651
Unresponsive to stimuli 12.11 11.70 6 50997 33810 63404209
Reflux gastritis 12.10 11.70 9 50994 1186 63436833
Poor peripheral circulation 12.10 11.70 15 50988 3734 63434285
Hospitalisation 12.08 11.70 32 50971 85049 63352970
Ageusia 12.07 11.70 31 50972 13697 63424322
Paraneoplastic syndrome 11.97 11.70 7 50996 616 63437403
Periodontitis 11.94 11.70 14 50989 3289 63434730
Pneumonitis 11.93 11.70 58 50945 35164 63402855
Mood swings 11.92 11.70 37 50966 18211 63419808
Renal vein thrombosis 11.86 11.70 6 50997 396 63437623
Dyshidrotic eczema 11.85 11.70 7 50996 627 63437392
Intentional self-injury 11.85 11.70 3 51000 25684 63412335
Ovarian neoplasm 11.85 11.70 8 50995 905 63437114
Granulocyte count decreased 11.81 11.70 9 50994 1231 63436788
Skin atrophy 11.79 11.70 17 50986 4889 63433130
Hyperthyroidism 11.75 11.70 32 50971 14641 63423378
Gingival ulceration 11.72 11.70 8 50995 922 63437097

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Growth retardation 86.52 25.60 20 1839 1828 34953244
Mesenteric vein thrombosis 78.04 25.60 16 1843 833 34954239
Performance enhancing product use 68.04 25.60 10 1849 67 34955005
Secondary hypogonadism 48.00 25.60 9 1850 293 34954779
Haematocrit increased 44.20 25.60 12 1847 2101 34952971
Metastases to bone 39.55 25.60 17 1842 11953 34943119
Spondylolisthesis 39.52 25.60 9 1850 768 34954304
Glucose tolerance decreased 37.60 25.60 6 1853 73 34954999
Breast cancer recurrent 36.37 25.60 5 1854 19 34955053
Autoimmune thyroiditis 35.82 25.60 9 1850 1165 34953907
Blood testosterone increased 35.10 25.60 9 1850 1264 34953808
Libido decreased 34.75 25.60 12 1847 4684 34950388
Oestradiol increased 31.24 25.60 5 1854 62 34955010
Product use issue 30.69 25.60 26 1833 63190 34891882
Off label use 30.67 25.60 68 1791 419456 34535616
Portal vein thrombosis 29.28 25.60 10 1849 3778 34951294
Osteonecrosis of jaw 27.37 25.60 15 1844 17874 34937198
Intentional product misuse 26.85 25.60 21 1838 45590 34909482
Androgenetic alopecia 26.53 25.60 3 1856 0 34955072
Insulin-like growth factor increased 25.72 25.60 7 1852 1236 34953836

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to bone 740.63 11.71 324 40968 24103 79678993
Malignant neoplasm progression 421.83 11.71 431 40861 135559 79567537
Metastases to liver 404.65 11.71 225 41067 28089 79675007
Metastases to lung 349.29 11.71 176 41116 17987 79685109
Hot flush 327.01 11.71 252 41040 54625 79648471
Breast cancer recurrent 273.61 11.71 89 41203 2888 79700208
Breast cancer metastatic 260.23 11.71 114 41178 8488 79694608
Breast cancer 236.65 11.71 171 41121 33610 79669486
Osteonecrosis 216.89 11.71 157 41135 30938 79672158
Bone pain 216.37 11.71 200 41092 55542 79647554
Arthralgia 192.62 11.71 691 40601 571112 79131984
Neoplasm progression 192.04 11.71 181 41111 51501 79651595
Metastases to lymph nodes 168.95 11.71 90 41202 10307 79692789
Tumour marker increased 156.99 11.71 65 41227 4207 79698889
Ejection fraction decreased 153.78 11.71 134 41158 34443 79668653
Osteonecrosis of jaw 152.25 11.71 147 41145 43079 79660017
White blood cell count decreased 151.31 11.71 314 40978 187974 79515122
Disease progression 149.97 11.71 309 40983 184053 79519043
Pseudocirrhosis 149.68 11.71 40 41252 640 79702456
Fatigue 142.24 11.71 893 40399 928834 78774262
Drug ineffective 125.59 11.71 231 41061 1080682 78622414
Tooth extraction 113.91 11.71 71 41221 10924 79692172
Metastases to spine 113.82 11.71 52 41240 4272 79698824
Alopecia 108.83 11.71 314 40978 231041 79472055
Osteopenia 108.58 11.71 84 41208 18280 79684816
Carbohydrate antigen 15-3 increased 103.30 11.71 34 41258 1145 79701951
Neutropenia 99.28 11.71 351 40941 287359 79415737
Completed suicide 89.49 11.71 11 41281 245756 79457340
Metastasis 83.03 11.71 49 41243 6831 79696265
Bone lesion 78.99 11.71 45 41247 5874 79697222
Vitreoretinal traction syndrome 75.87 11.71 13 41279 14 79703082
Toxicity to various agents 74.82 11.71 65 41227 421475 79281621
Tonsillar disorder 74.05 11.71 27 41265 1239 79701857
Trigger finger 72.51 11.71 38 41254 4207 79698889
Neuropathy peripheral 71.47 11.71 197 41095 141108 79561988
Infusion related reaction 67.31 11.71 18 41274 230219 79472877
Lacrimation increased 65.48 11.71 69 41223 22408 79680688
Lymphoedema 65.27 11.71 53 41239 12360 79690736
Retinal toxicity 64.06 11.71 25 41267 1386 79701710
Osteolysis 62.19 11.71 35 41257 4463 79698633
Therapeutic product effect decreased 60.46 11.71 7 41285 163856 79539240
Cystoid macular oedema 59.10 11.71 26 41266 1954 79701142
Metastases to pleura 58.30 11.71 24 41268 1530 79701566
Synovitis 56.72 11.71 6 41286 150728 79552368
Endometrial hyperplasia 54.35 11.71 18 41274 618 79702478
Vulvovaginal dryness 53.10 11.71 25 41267 2199 79700897
Bone disorder 52.72 11.71 57 41235 19056 79684040
Maternal exposure during pregnancy 52.51 11.71 5 41287 136533 79566563
Pain in jaw 51.97 11.71 89 41203 46062 79657034
Malignant pleural effusion 51.39 11.71 28 41264 3352 79699744
Nasal disorder 51.22 11.71 29 41263 3740 79699356
Invasive ductal breast carcinoma 51.03 11.71 34 41258 5858 79697238
Hypotension 50.93 11.71 94 41198 440223 79262873
Nausea 49.36 11.71 731 40561 956465 78746631
Treatment failure 46.76 11.71 15 41277 170471 79532625
Fasciitis 45.93 11.71 17 41275 814 79702282
Metastases to central nervous system 45.46 11.71 49 41243 16326 79686770
Myalgia 45.02 11.71 203 41089 185438 79517658
Nail disorder 44.93 11.71 42 41250 11810 79691286
Peritoneal disorder 44.20 11.71 16 41276 719 79702377
Vaginal discharge 43.81 11.71 34 41258 7429 79695667
Oestradiol increased 42.01 11.71 10 41282 97 79702999
Intentional overdose 40.42 11.71 4 41288 105956 79597140
Systemic lupus erythematosus 40.42 11.71 7 41285 121142 79581954
Sialoadenitis 40.25 11.71 20 41272 1981 79701115
Drug abuse 40.09 11.71 17 41275 162674 79540422
Oestrogen receptor assay positive 39.19 11.71 12 41280 318 79702778
Uterine polyp 38.42 11.71 18 41274 1566 79701530
Acute myeloid leukaemia 38.03 11.71 62 41230 30823 79672273
Pleural neoplasm 37.91 11.71 12 41280 356 79702740
Hypertensive angiopathy 36.79 11.71 9 41283 99 79702997
Breast pain 36.67 11.71 32 41260 8233 79694863
Pneumonia 36.54 11.71 197 41095 660049 79043047
Metastases to breast 36.42 11.71 11 41281 278 79702818
Musculoskeletal chest pain 35.05 11.71 53 41239 24711 79678385
Metastases to pelvis 34.61 11.71 13 41279 649 79702447
Mouth swelling 34.29 11.71 27 41265 6024 79697072
Excessive eye blinking 34.21 11.71 17 41275 1684 79701412
Carpal tunnel syndrome 33.82 11.71 46 41246 19482 79683614
Debridement 33.80 11.71 17 41275 1728 79701368
Dry skin 33.56 11.71 94 41198 67901 79635195
Metastases to chest wall 33.28 11.71 12 41280 533 79702563
Second primary malignancy 33.10 11.71 39 41253 14311 79688785
Mesenteric vein thrombosis 33.06 11.71 17 41275 1810 79701286
Intentional product use issue 32.79 11.71 19 41273 152093 79551003
Oral pain 32.79 11.71 59 41233 31739 79671357
Pericarditis 32.70 11.71 7 41285 104229 79598867
Rheumatoid arthritis 32.48 11.71 36 41256 208434 79494662
Vitreous detachment 32.38 11.71 18 41274 2241 79700855
Full blood count decreased 31.89 11.71 53 41239 26766 79676330
Hair growth abnormal 31.44 11.71 19 41273 2765 79700331
Nail infection 31.37 11.71 18 41274 2381 79700715
Hyperparathyroidism primary 31.33 11.71 11 41281 452 79702644
Drug hypersensitivity 30.94 11.71 68 41224 298848 79404248
Osteoporosis 30.94 11.71 79 41213 54033 79649063
Dental care 30.49 11.71 13 41279 905 79702191
Joint neoplasm 29.88 11.71 7 41285 63 79703033
Nail avulsion 29.88 11.71 8 41284 129 79702967
Hair texture abnormal 29.66 11.71 20 41272 3514 79699582
Acute phase reaction 29.59 11.71 10 41282 366 79702730
Progesterone receptor assay positive 29.38 11.71 9 41283 239 79702857
Human epidermal growth factor receptor negative 29.37 11.71 5 41287 5 79703091
Joint stiffness 29.17 11.71 65 41227 40765 79662331
Cardio-respiratory arrest 28.95 11.71 10 41282 108500 79594596
Osteomyelitis 28.94 11.71 57 41235 32808 79670288
PIK3CA-activated mutation 28.49 11.71 11 41281 592 79702504
Overdose 28.48 11.71 32 41260 184174 79518922
Leiomyosarcoma recurrent 28.06 11.71 5 41287 8 79703088
Soft tissue neoplasm 27.98 11.71 7 41285 85 79703011
Off label use 27.97 11.71 318 40974 906897 78796199
Sequestrectomy 27.95 11.71 12 41280 850 79702246
Breast cancer female 27.86 11.71 32 41260 11429 79691667
Catheter site bruise 27.66 11.71 10 41282 448 79702648
Metastatic neoplasm 27.51 11.71 22 41270 5020 79698076
Resorption bone increased 27.49 11.71 14 41278 1461 79701635
Joint swelling 27.21 11.71 69 41223 288577 79414519
Pyrexia 27.21 11.71 223 41069 678486 79024610
Atypical femur fracture 26.95 11.71 22 41270 5167 79697929
Tendonitis 26.88 11.71 46 41246 23784 79679312
Bone sequestrum 26.86 11.71 13 41279 1216 79701880
Pathological fracture 26.60 11.71 30 41262 10507 79692589
Portal hypertension 26.58 11.71 25 41267 7083 79696013
Full blood count abnormal 26.23 11.71 62 41230 40412 79662684
Secondary hypogonadism 25.86 11.71 9 41283 360 79702736
Septic shock 25.54 11.71 16 41276 122785 79580311
Tumour marker decreased 25.51 11.71 6 41286 55 79703041
Metastases to skin 25.32 11.71 14 41278 1725 79701371
Red blood cell count decreased 25.01 11.71 76 41216 57437 79645659
Radiation skin injury 24.96 11.71 13 41279 1421 79701675
Metastases to soft tissue 24.88 11.71 10 41282 599 79702497
Metastases to the mediastinum 24.87 11.71 10 41282 600 79702496
Pancreatic neoplasm 24.61 11.71 13 41279 1463 79701633
Periodontal disease 24.37 11.71 14 41278 1856 79701240
Sepsis 24.18 11.71 66 41226 269362 79433734
Diarrhoea 24.10 11.71 611 40681 879878 78823218
Growth retardation 23.87 11.71 14 41278 1929 79701167
Glucose tolerance decreased 23.75 11.71 6 41286 76 79703020
Tooth disorder 23.71 11.71 46 41246 26187 79676909
Papilloedema 23.46 11.71 22 41270 6211 79696885
Ascites 23.30 11.71 89 41203 75473 79627623
Fibrous histiocytoma 23.28 11.71 10 41282 709 79702387
Back pain 23.11 11.71 250 41042 303930 79399166
Intraductal proliferative breast lesion 23.10 11.71 15 41277 2476 79700620
Retinal detachment 22.78 11.71 26 41266 9221 79693875
Haemorrhoids 22.66 11.71 48 41244 29080 79674016
Organising pneumonia 22.42 11.71 28 41264 10911 79692185
Acute kidney injury 22.02 11.71 168 41124 519236 79183860
Oestradiol abnormal 21.87 11.71 5 41287 40 79703056
Meningioma 21.86 11.71 18 41274 4280 79698816
Recall phenomenon 21.79 11.71 11 41281 1126 79701970
Interstitial lung disease 21.46 11.71 115 41177 112485 79590611
Asthenia 21.43 11.71 378 40914 511311 79191785
Metastases to retroperitoneum 21.36 11.71 8 41284 396 79702700
Febrile neutropenia 21.16 11.71 56 41236 230943 79472153
Psoriatic arthropathy 21.13 11.71 7 41285 77992 79625104
Uterine leiomyoma 20.97 11.71 21 41271 6422 79696674
Ischaemic stroke 20.65 11.71 50 41242 33081 79670015
Palmar-plantar erythrodysaesthesia syndrome 20.65 11.71 50 41242 33084 79670012
Cardiac arrest 20.52 11.71 36 41256 172060 79531036
Bone debridement 20.44 11.71 8 41284 447 79702649
Carbohydrate antigen 27.29 increased 20.44 11.71 5 41287 55 79703041
Polymyositis 20.41 11.71 15 41277 3021 79700075
Stomatitis 20.37 11.71 138 41154 146619 79556477
Confusional state 20.36 11.71 90 41202 317907 79385189
Breast mass 20.14 11.71 21 41271 6733 79696363
Product substitution issue 20.14 11.71 37 41255 20219 79682877
Invasive lobular breast carcinoma 20.14 11.71 9 41283 702 79702394
Neoplasm recurrence 20.09 11.71 17 41275 4197 79698899
General physical health deterioration 20.08 11.71 74 41218 275164 79427932
Cutaneous vasculitis 19.99 11.71 23 41269 8229 79694867
Ovarian mass 19.99 11.71 8 41284 474 79702622
Tumour marker abnormal 19.95 11.71 7 41285 287 79702809
Dysgeusia 19.86 11.71 70 41222 57107 79645989
Hyperkalaemia 19.82 11.71 18 41274 114380 79588716
Superinfection 19.80 11.71 18 41274 4884 79698212
Carcinoembryonic antigen increased 19.74 11.71 13 41279 2196 79700900
Transient acantholytic dermatosis 19.71 11.71 6 41286 156 79702940
Recurrent cancer 19.69 11.71 14 41278 2679 79700417
Breast haemorrhage 19.56 11.71 6 41286 160 79702936
Antisynthetase syndrome 19.35 11.71 6 41286 166 79702930
Madarosis 19.19 11.71 14 41278 2788 79700308
Metastases to uterus 19.13 11.71 5 41287 73 79703023
Actinomycosis 19.06 11.71 10 41282 1109 79701987
Folliculitis 18.91 11.71 3 41289 55377 79647719
Metastases to bone marrow 18.89 11.71 9 41283 813 79702283
Jaw operation 18.82 11.71 9 41283 820 79702276
Gingival swelling 18.77 11.71 17 41275 4592 79698504
Pleural effusion 18.64 11.71 134 41158 145128 79557968
Chronic inflammatory demyelinating polyradiculoneuropathy 18.53 11.71 10 41282 1175 79701921
Performance enhancing product use 18.48 11.71 5 41287 84 79703012
Gastrointestinal haemorrhage 18.44 11.71 30 41262 147689 79555407
Blood oestrogen increased 18.37 11.71 5 41287 86 79703010
Blood pressure fluctuation 18.24 11.71 6 41286 67139 79635957
Sinusitis 18.21 11.71 47 41245 195454 79507642
Hypersensitivity 18.16 11.71 72 41220 262167 79440929
Rhabdomyolysis 18.14 11.71 16 41276 103115 79599981
Mood swings 18.13 11.71 35 41257 19845 79683251
Hepatic lesion 17.88 11.71 20 41272 6939 79696157
Oroantral fistula 17.83 11.71 7 41285 394 79702702
Mucosal inflammation 17.81 11.71 82 41210 75498 79627598
Vertebral column mass 17.71 11.71 6 41286 221 79702875
Pain in extremity 17.71 11.71 276 41016 364262 79338834
Spondylolisthesis 17.63 11.71 14 41278 3161 79699935
Neuroectodermal neoplasm 17.62 11.71 3 41289 3 79703093
Metastases to peritoneum 17.56 11.71 16 41276 4356 79698740
Autoimmune pancreatitis 17.45 11.71 8 41284 662 79702434
Gene mutation 17.45 11.71 13 41279 2673 79700423
Decreased appetite 17.31 11.71 261 41031 342157 79360939
Unresponsive to stimuli 16.99 11.71 4 41288 55784 79647312
Borrelia infection 16.99 11.71 6 41286 251 79702845
Osteosclerosis 16.87 11.71 15 41277 3956 79699140
Metabolic acidosis 16.82 11.71 11 41281 82518 79620578
Hypoaesthesia teeth 16.61 11.71 4 41288 41 79703055
Cholestasis 16.58 11.71 62 41230 52047 79651049
Hydrothorax 16.53 11.71 10 41282 1458 79701638
Spinal pain 16.43 11.71 29 41263 15363 79687733
Vitreous adhesions 16.27 11.71 4 41288 45 79703051
Abdominal wall cyst 16.27 11.71 4 41288 45 79703051
Oestradiol decreased 16.09 11.71 3 41289 7 79703089
Hair colour changes 16.05 11.71 15 41277 4217 79698879
Mastectomy 16.02 11.71 9 41283 1143 79701953
Pustule 15.91 11.71 11 41281 2014 79701082
Poor peripheral circulation 15.82 11.71 14 41278 3669 79699427
Muscle injury 15.77 11.71 3 41289 48558 79654538
Respiratory failure 15.71 11.71 45 41247 180866 79522230
Exposed bone in jaw 15.70 11.71 14 41278 3706 79699390
C-reactive protein abnormal 15.68 11.71 3 41289 48364 79654732
Toothache 15.64 11.71 33 41259 19937 79683159
Drug intolerance 15.57 11.71 77 41215 264042 79439054
Rhabdomyosarcoma 15.46 11.71 5 41287 159 79702937
Portal vein thrombosis 15.41 11.71 17 41275 5810 79697286
Benign lymph node neoplasm 15.31 11.71 3 41289 10 79703086
Henoch-Schonlein purpura 15.16 11.71 12 41280 2698 79700398
Retinopathy 15.16 11.71 14 41278 3877 79699219
Ovarian cancer 15.03 11.71 14 41278 3920 79699176
Pneumonia aspiration 14.95 11.71 8 41284 66959 79636137
Breast cancer in situ 14.84 11.71 8 41284 938 79702158
Polycythaemia 14.72 11.71 11 41281 2273 79700823
Granulocyte count decreased 14.62 11.71 10 41282 1798 79701298
Breast swelling 14.52 11.71 9 41283 1371 79701725
C-reactive protein increased 14.48 11.71 28 41264 128999 79574097
Disease recurrence 14.47 11.71 53 41239 44056 79659040
Lichen sclerosus 14.46 11.71 8 41284 986 79702110
Neuralgia 14.40 11.71 44 41248 33340 79669756
Urinary casts present 14.37 11.71 4 41288 75 79703021
Squamous cell breast carcinoma 14.33 11.71 3 41289 15 79703081
Tooth loss 14.32 11.71 18 41274 7057 79696039
Tremor 14.27 11.71 43 41249 170040 79533056
Hypercalcaemia 14.17 11.71 48 41244 38382 79664714
Chronic hepatitis 14.12 11.71 9 41283 1438 79701658
Blood testosterone increased 14.04 11.71 8 41284 1044 79702052
Urticaria 14.02 11.71 49 41243 185152 79517944
Meibomian gland dysfunction 14.00 11.71 5 41287 216 79702880
Coma 13.96 11.71 19 41273 100630 79602466
Sjogren's syndrome 13.87 11.71 7 41285 717 79702379
Vascular purpura 13.75 11.71 12 41280 3086 79700010
Postoperative wound complication 13.75 11.71 9 41283 1505 79701591
Bone marrow infiltration 13.67 11.71 7 41285 739 79702357
Product use in unapproved indication 13.63 11.71 75 41217 250284 79452812
Autoimmune hepatitis 13.63 11.71 23 41269 11760 79691336
Electrocardiogram QT interval 13.62 11.71 5 41287 234 79702862
Loss of personal independence in daily activities 13.60 11.71 20 41272 102560 79600536
Intermenstrual bleeding 13.59 11.71 16 41276 5868 79697228
Multiple organ dysfunction syndrome 13.57 11.71 26 41266 120220 79582876
Dental caries 13.57 11.71 23 41269 11797 79691299
Tachycardia 13.48 11.71 47 41245 177721 79525375
Sedation 13.47 11.71 5 41287 51890 79651206
White blood cell disorder 13.44 11.71 12 41280 3180 79699916
Cutaneous sarcoidosis 13.44 11.71 6 41286 467 79702629
Uveitis 13.40 11.71 28 41264 16802 79686294
Lower limb fracture 13.38 11.71 34 41258 23181 79679915
BRCA2 gene mutation 13.36 11.71 4 41288 98 79702998
Varicophlebitis 13.35 11.71 3 41289 22 79703074
Dark circles under eyes 13.27 11.71 6 41286 481 79702615
Suicide attempt 13.26 11.71 14 41278 82918 79620178
Drug ineffective for unapproved indication 13.19 11.71 5 41287 51233 79651863
Cytomegalovirus infection 13.10 11.71 3 41289 42641 79660455
Metastases to eye 13.08 11.71 5 41287 262 79702834
Cardiotoxicity 12.99 11.71 23 41269 12216 79690880
Pelvic mass 12.95 11.71 8 41284 1211 79701885
Injection site pruritus 12.94 11.71 3 41289 42280 79660816
Left ventricular dysfunction 12.91 11.71 30 41262 19331 79683765
Medication error 12.87 11.71 10 41282 68632 79634464
Visual acuity reduced 12.86 11.71 39 41253 29430 79673666
Blood alkaline phosphatase increased 12.80 11.71 66 41226 63598 79639498
Injection site erythema 12.73 11.71 13 41279 78184 79624912
Agitation 12.68 11.71 20 41272 99695 79603401
Bacteriuria 12.64 11.71 8 41284 1263 79701833
Plantar fasciitis 12.61 11.71 12 41280 3448 79699648
Rouleaux formation 12.61 11.71 3 41289 29 79703067
Blood copper increased 12.61 11.71 3 41289 29 79703067
Adenomyosis 12.51 11.71 5 41287 295 79702801
Wheezing 12.50 11.71 26 41266 116638 79586458
Paraesthesia 12.50 11.71 143 41149 176180 79526916
Bronchitis 12.47 11.71 31 41261 130613 79572483
Wound 12.36 11.71 26 41266 116153 79586943
Renal vein thrombosis 12.36 11.71 6 41286 565 79702531
Wrong technique in product usage process 12.35 11.71 12 41280 73863 79629233
Subacute cutaneous lupus erythematosus 12.32 11.71 12 41280 3549 79699547
Visual field defect 12.29 11.71 19 41273 9026 79694070
Alopecia areata 12.15 11.71 9 41283 1834 79701262
Vertigo 12.12 11.71 69 41223 69013 79634083
Dyshidrotic eczema 12.05 11.71 6 41286 597 79702499
Heart rate increased 12.04 11.71 28 41264 120696 79582400
Dysaesthesia 12.03 11.71 15 41277 5833 79697263
Oxygen saturation decreased 12.03 11.71 31 41261 129016 79574080
Mucosal ulceration 12.02 11.71 9 41283 1864 79701232
Arthropathy 12.02 11.71 49 41243 177062 79526034
Uterine cancer 11.96 11.71 12 41280 3679 79699417
Peripheral sensory neuropathy 11.95 11.71 23 41269 13010 79690086
Meniscus injury 11.80 11.71 16 41276 6752 79696344
Dupuytren's contracture 11.80 11.71 3 41289 39 79703057
Irritable bowel syndrome 11.76 11.71 9 41283 62232 79640864

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L02BG03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Aromatase inhibitors
FDA MoA N0000175080 Aromatase Inhibitors
FDA EPC N0000175563 Aromatase Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:50790 aromatase inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018931 Antineoplastic Agents, Hormonal
MeSH PA D047072 Aromatase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D004965 Estrogen Antagonists
MeSH PA D006727 Hormone Antagonists
MeSH PA D065088 Steroid Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hormone receptor positive malignant neoplasm of breast indication 417181009
Malignant tumor of ovary off-label use 363443007 DOID:2394
Hypercholesterolemia contraindication 13644009
Pregnancy, function contraindication 289908002
Osteopenia contraindication 312894000
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.56 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Aromatase Enzyme INHIBITOR IC50 6.22 WOMBAT-PK CHEMBL

External reference:

IDSource
4020948 VUID
N0000148427 NUI
D00960 KEGG_DRUG
262485 RXNORM
C0290883 UMLSCUI
CHEBI:2704 CHEBI
CHEMBL1399 ChEMBL_ID
DB01217 DRUGBANK_ID
D000077384 MESH_DESCRIPTOR_UI
2187 PUBCHEM_CID
5137 IUPHAR_LIGAND_ID
7274 INN_ID
2Z07MYW1AZ UNII
173198 MMSL
4200 MMSL
5599 MMSL
d03873 MMSL
108774000 SNOMEDCT_US
386910003 SNOMEDCT_US
4020948 VANDF
005094 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 0093-7536 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 0093-7536 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections
ARIMIDEX HUMAN PRESCRIPTION DRUG LABEL 1 0310-0201 TABLET 1 mg ORAL NDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 0781-5356 TABLET, FILM COATED 1 mg ORAL ANDA 29 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6195 TABLET 1 mg ORAL ANDA 26 sections
Anastrozole Human Prescription Drug Label 1 16571-421 TABLET 1 mg ORAL ANDA 29 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 16729-035 TABLET 1 mg ORAL ANDA 26 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 21695-990 TABLET 1 mg ORAL ANDA 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 23155-857 TABLET 1 mg ORAL ANDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 42254-161 TABLET 1 mg ORAL ANDA 28 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 42291-016 TABLET 1 mg ORAL ANDA 32 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 42291-085 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 42291-085 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 43063-383 TABLET 1 mg ORAL ANDA 33 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 43063-383 TABLET 1 mg ORAL ANDA 33 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 43063-383 TABLET 1 mg ORAL ANDA 33 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 45865-909 TABLET 1 mg ORAL ANDA 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 50090-2453 TABLET 1 mg ORAL ANDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 50090-2453 TABLET 1 mg ORAL ANDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 50090-2453 TABLET 1 mg ORAL ANDA 28 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 50090-5002 TABLET 1 mg ORAL ANDA 30 sections
Anastrozole Human Prescription Drug Label 1 50090-5812 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections
Anastrozole Human Prescription Drug Label 1 50090-5812 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 50268-075 TABLET 1 mg ORAL ANDA 31 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 51655-638 TABLET 1 mg ORAL ANDA 15 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 51991-620 TABLET 1 mg ORAL ANDA 33 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 51991-620 TABLET 1 mg ORAL ANDA 33 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 51991-620 TABLET 1 mg ORAL ANDA 33 sections
ARIMIDEX HUMAN PRESCRIPTION DRUG LABEL 1 54868-5000 TABLET 1 mg ORAL NDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 54868-6130 TABLET 1 mg ORAL ANDA 27 sections